



02-16-06

1743  
TFLW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission 11

Application Number	10/068,663
Filing Date	Feb. 6, 2002
First Named Inventor	Chuan Li
Art Unit	1743
Examiner Name	Maureen M. Wallenhorst
Attorney Docket Number	

## ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input type="checkbox"/> Other Enclosure(s) (please identify below):
<div>Remarks</div>		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name			
Signature			
Printed name	Chuan Li <i>Chuan Li</i>		
Date	February 15, 2006	Reg. No.	

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	<i>Chuan Li</i>		
Typed or printed name	Chuan Li	Date	February 15, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Amendments to a continuation of application PROTEIN STANDARD FOR  
ESTIMATING SIZE AND MASS

Applicant Name: Chuan Li

Date: February 15, 2006

Application/Control Number: 10/068,663

Art Unit: 1743

**a.) Introductory Comments**

1. In Examples 1-3, different known amounts of BSA run in separate lanes. For example, 10 micrograms of BSA run in one lane, 5 micrograms of BSA run in another lane, 2 micrograms of BSA run in yet another lane on one gel. The one of ordinary skill in the art will understand that the more different amounts of BSA are used, the more accurate the quantity estimation will be.

The polypeptides in the protein standard will need to run on separate lanes than the different amounts of BSA if their sizes are same or similar to BSA. The polypeptides in the protein standard can run on the same lanes as the different amounts of BSA if their sizes are different than BSA. They may also run on the different lanes too. The polypeptides and BSA will not interfere with each other on staining intensities (quantity estimation) even on the same lane if their sizes are different.

The staining intensities of the polypeptides in the protein standard are compared with the staining intensities of different known amount of BSA to estimate the quantities of polypeptides in the protein standard. The amount of each of the different polypeptides in the protein standard is expressed as equivalent amount of BSA. The amount of ovalbumin in the protein standard of Example 1 is expressed as the same staining intensity of a known amount of BSA such as 5 micrograms. In other words, the true quantity of ovalbumin is not expressed in the protein standard. Many protein assays use known amounts of a known protein as standard. Whenever known amounts of a known protein are used as standard in protein quantification, the quantities of the estimated proteins represent the equivalent amounts of the known protein used. The applicant believes that it is a common knowledge of the one of ordinary skill in the art. Therefore it is not described in the original specification. By following the experimental procedures in

the Examples of the specification as originally filed, one of ordinary skill in the art will be able to make and use the protein standard described in the application. The phrases “The amounts of polypeptides in the protein standard represent the equivalent amounts of BSA used in the quantity estimation.” are added in Examples 1-3 after the protein estimation for explanation of the meaning as directed by the examiner.

Claim 22 is cancelled to avoid containing new matter.

In Claim 30, the word “IgG” is changed to the word “insulin” to avoid new matter. Insulin is described to be used as a protein standard in the DETAILED DESCRIPTION OF THE INVENTION of the specification (second paragraph on page 9).

2. In claim 21, part (d) is deleted to avoid being indefinite and unclear.

In part (b) of claim 21, the phrase “the size of all of the polypeptides covers a range that is separable by a given polyacrylamide gel electrophoresis;” is changed to “the size of all of the polypeptides covers a range that is separable by a given polyacrylamide gel electrophoresis; and” to make proper sense.

In part (c) of claim 21, the phrase “the amounts of all of the polypeptides cover a range that is detectable by a given detection assay; and” is changed to “the amounts of all of the polypeptides cover a range that is detectable by a given detection assay.” to make proper sense.

Claim 23 is cancelled because of deletion of part (d) of claim 21.

In claim 29, the phrase “by comparing the staining intensities of the polypeptides with the staining intensities of the different amounts of the known protein” is added to avoid being indefinite and to make the claim clear.

In claim 30, the phrase “a commonly used quantity standard protein such as” is deleted to avoid being indefinite.

3. In claim 25, the phrase “at least one container means contains the protein standard according to” is changed to “at least one container means containing the protein standard according to” according to the suggestion.

In claim 26, the phrase “the polypeptide in a protein sample” is changed to “a polypeptide in a protein sample” to address antecedent basis.

Claim 32 is cancelled to avoid being indefinite.

In conclusion, the claims of the disclosed invention are changed or cancelled according to the suggestions and to avoid being indefinite and unclear. Therefore Claims 21, 26 and 29 are patentable. Claims 24-25, 27-28 and 30-38 are dependent on Claims 21, 26 and 29. They are provided for fully disclosure of the invention, therefore they are also patentable. If the examiner agrees but does not feel that the present claims are technically adequate, applicant respectfully requests that the examiner write acceptable claims pursuant to MPEP 707.07(j).